Human natural CD4+CD25+ regulatory T-cell (T-reg) therapy (University of Minnesota)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameHuman natural CD4+CD25+ regulatory T-cell (T-reg) therapy (University of Minnesota)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tregs
Mechanisms of ActionImmunosuppressants
TargetsNot applicable
Therapy Area/IndicationsGraft vs Host DiseaseRejection of liver transplantation
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Minnesota
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of Minnesota
Active IndicationsN/A
Inactive IndicationsGraft vs Host DiseaseRejection of liver transplantation

Other Information

ATC CodeN/A
Related LinksN/A